- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Sonus and HP finish contrast trial
Developmental work continues on EchoGen, an ultrasound contrast agent from Sonus Pharmaceuticals. In conjunction with ultrasound scanner vendor Hewlett-Packard, Sonus has completed an image optimization trial that has determined the scanner control
Developmental work continues on EchoGen, an ultrasound contrast agent from Sonus Pharmaceuticals. In conjunction with ultrasound scanner vendor Hewlett-Packard, Sonus has completed an image optimization trial that has determined the scanner control parameters required to provide the highest level of cardiac image enhancement using its EchoGen ultrasound contrast agent.
The trial, which was conducted at the VA Medical Center in Dallas, consisted of 18 patients who were given EchoGen and then scanned using an HP Sonos 2500 LE echocardiography scanner. Sonos 2500 LE was designed for use in harmonic imaging studies with ultrasound contrast (SCAN 7/3/96).
In addition to determining optimal system settings, researchers found that on average, EchoGen demonstrated a persistence of at least five minutes, according to Sonus, which is headquartered in Bothell, WA.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
